{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:47:13Z","timestamp":1793908033237,"version":"4.8.0"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Common variable immunodeficiency (CVID) associated liver disease is an underrecognized and poorly studied non-infectious complication that lacks an established treatment. We describe a CVID patient with severe multiorgan complications, including non-cirrhotic portal hypertension secondary to nodular regenerative hyperplasia leading to diuretic-refractory ascites. Remarkably, treatment with rituximab, administered for concomitant immune thrombocytopenia, resulted in the complete and sustained resolution of portal hypertension and ascites. Our case, complemented with a literature review, suggests a beneficial effect of rituximab that warrants further research.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1264482","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T04:37:38Z","timestamp":1695184658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable immunodeficiency: a case report and literature study"],"prefix":"10.3389","volume":"14","author":[{"given":"Willem","family":"Roosens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sien","family":"Van Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Humblet-Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadewijch","family":"De Samblanx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Verslype","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"van Malenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schalk","family":"van der Merwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Laleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Schrijvers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00338","article-title":"Heterogeneity of liver disease in common variable immunodeficiency disorders","volume":"11","author":"Pecoraro","year":"2020","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/j.jaip.2019.04.016","article-title":"Liver disease is common in patients with common variable immunodeficiency and predicts mortality in the presence of cirrhosis or portal hypertension","volume":"7","author":"Azzu","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00149","article-title":"Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis","volume":"11","author":"Ho","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.251","article-title":"Nodular regenerative hyperplasia in CVID patients: could low-dose oral glucocorticoids be part of the solution","author":"Sousa eSilva","year":"2022","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2198208","article-title":"Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives","volume":"19","author":"Fevang","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12948-019-0113-3","article-title":"Immunosuppressive therapy with rituximab in common variable immunodeficiency","volume":"17","author":"Pecoraro","year":"2019","journal-title":"Clin Mol Allergy: CMA"},{"key":"B7","article-title":"Successful rituximab treatment of granulomatous\/lymphocytic interstitial lung disease in common variable immunodeficiency","volume":"67","author":"Kr\u00e1l\u00ed\u010dkov\u00e1","year":"2018","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"bcr2016215624","DOI":"10.1136\/bcr-2016-215624","article-title":"Management of granulomatous lymphocytic interstitial lung disease in a patient with common variable immune deficiency","author":"Pathria","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s10875-012-9778-9","article-title":"Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients","volume":"33","author":"Boursiquot","year":"2013","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1264482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T04:37:40Z","timestamp":1695184660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1264482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":9,"alternative-id":["10.3389\/fimmu.2023.1264482"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1264482","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"article-number":"1264482"}}